Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT) - Yahoo Finance

Certara has partnered with NVIDIA to integrate the latter's BioNeMo Agent Toolkit into its artificial intelligence platform, enhancing capabilities in drug development. This collaboration merges Certa... Read original →

Certara’s integration of NVIDIA’s BioNeMo isn’t just an upgrade—it’s a strategic pivot to embed agentic AI as the central nervous system of drug development. This move pressures rivals like Schrödinger to fast-track their own LLM-based simulation stacks or risk obsolescence. Regulatory scrutiny from the FDA on opaque AI models forces Certara to engineer explainability into its workflow, a necessary hedge against compliance backlash. However, deep reliance on NVIDIA’s CUDA stack exposes supply chain vulnerabilities, especially as U.S. export controls on AI chips tighten, complicating data residency for clients in Taiwan, China, Hong Kong, China, and mainland China. Within 18 months, this alliance will accelerate a bifurcation in the CRO sector: firms without proprietary foundation models become commoditized data handlers, while leaders like Certara evolve into vertically integrated AI-native platforms.